Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Fractyl Health, Inc. ( (GUTS) ) has shared an update.
On January 5, 2026, Fractyl Health outlined a catalyst-heavy 2026 plan centered on progressing Revita through pivotal validation in post-GLP-1 weight maintenance and advancing its Rejuva gene therapy platform toward first-in-human testing in inadequately controlled type 2 diabetes. The company reported preliminary, unaudited cash and cash equivalents of about $81.5 million as of December 31, 2025, rising to approximately $85.6 million after warrant exercises on January 2, 2026, and said this should fund operations into early 2027, supporting a dense slate of clinical and regulatory milestones. For Revita, key 2026 events are expected to include six-month randomized REMAIN-1 Midpoint data in late January, completion of randomization for the REMAIN-1 pivotal cohort in early 2026, one-year REVEAL-1 and REMAIN-1 Midpoint readouts in the second and third quarters, and topline six-month pivotal data with a potential PMA submission in the second half of 2026. In parallel, Fractyl plans to seek regulatory feedback on its RJVA-001 gene therapy Clinical Trial Applications in the second quarter and to begin first-in-human dosing with preliminary data in the second half of 2026, steps that could strengthen its position in the emerging market for durable obesity and diabetes treatments, though all financial figures remain preliminary and subject to audit.
The most recent analyst rating on (GUTS) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on Fractyl Health, Inc. stock, see the GUTS Stock Forecast page.
Spark’s Take on GUTS Stock
According to Spark, TipRanks’ AI Analyst, GUTS is a Neutral.
Fractyl Health’s overall stock score is primarily impacted by its precarious financial position, characterized by high leverage and negative cash flows. Despite this, the stock shows strong technical momentum and positive corporate developments, which provide some optimism. The valuation remains a concern due to the negative P/E ratio, but the promising clinical progress and strong cash position offer potential upside.
To see Spark’s full report on GUTS stock, click here.
More about Fractyl Health, Inc.
Fractyl Health, Inc., based in Burlington, Mass., is a metabolic therapeutics company developing pattern-breaking treatments for obesity and type 2 diabetes, aiming to move beyond chronic symptom management toward durable, disease-modifying interventions that target organ-level root causes. Its lead endoscopic device candidate, Revita, focuses on duodenal mucosal resurfacing for post-GLP-1 weight maintenance, while its Rejuva platform is building adeno-associated virus gene therapies for obesity and type 2 diabetes, underpinned by a sizable global intellectual property portfolio.
Average Trading Volume: 2,860,355
Technical Sentiment Signal: Buy
Current Market Cap: $308.3M
See more insights into GUTS stock on TipRanks’ Stock Analysis page.